Revenue - Viatris Agreement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%
Maximum potential payments receivable	$ 205,000
Izencitinib | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	150,000
Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	160,000
Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	45,000
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	160,000
YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	10,000
Development and Commercialization Agreement | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	7,500
Development and Commercialization Agreement | YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	7,500
Development and Commercialization Agreement | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	$ 37,500
Viatris
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	65.00%
Upfront payment receivable	$ 52,500
Maximum potential payments receivable	45,000
Viatris | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	$ 14,503	$ 10,411
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%
Revenues	$ 19,329	$ 16,434
Maximum potential payments receivable	$ 45,000